{"success":true,"data":{"pressRelease":{"id":"89455","rtpr_id":"nBwhpsgfa","ticker":"MEDCL","exchange":"Euronext Paris","all_tickers":["MEDCL"],"title":"Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory","author":"Business Wire","published_at":"2026-07-15T15:45:00.093Z","article_body":"Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory\n\nMore than 3 years extension of debt maturity to mid-2031, aligning it with\nexpected revenue ramp-up primarily driven by marketed UZEDY(®) and Olanzapine\nLAI, which is currently under regulatory review in the U.S. and Europe\n\n€28 million in non-dilutive new bank loans secured from leading European\ncommercial banks\n\nEarly repayment of half of the €40 million European Investment Bank (EIB)\ncredit facility and the related capitalized interest, originally maturing in\nDecember 2027\n\nRegulatory News:\n\nMedincell (Euronext Paris: MEDCL) today announced the completion of\nnon-dilutive financing transactions designed to strengthen its financing\nprofile and align debt maturities with the Company's expected revenue growth\ntrajectory and future cash flows. These cash flows are expected to be\nprimarily driven by milestones and royalties from UZEDY(®), which is already\nmarketed, and from Olanzapine LAI, currently under regulatory review in the\nU.S., with approval anticipated in Q4 2026. Both products are partnered with\nTeva.\n\nThe Company has secured €28 million in non-dilutive loans with leading\nEuropean commercial banks, with no covenant or equity-linked instruments\nattached, strengthening its long-term cash position. In parallel, the Company\nwill repay a €20 million tranche, together with related capitalized\ninterests, of its existing €40 million European Investment Bank (EIB) credit\nfacility entered into in 2022, by the end of July 2026.\n\nChristophe Douat, CEO of Medincell, said: “This is a natural step in\nexecuting our ‘Shift to Growth’ strategy. As UZEDY sales continue to ramp\nup and we move closer to the potential commercial launch of Olanzapine LAI by\nour partner Teva, we are aligning our financial structure with our expected\nrevenue growth. This strengthens our flexibility and supports the continued\nadvancement of our pipeline of innovative products, aimed at generating\nrecurring, high-margin revenues over time and creating sustainable long-term\nvalue.”\n\nStéphane Postic, CFO of Medincell, said: “These non-dilutive debt financing\ntransactions reflect the continued execution of a long-term financing strategy\naligned with Medincell’s growth trajectory. As of March 31, 2026, we held\n€84.8 million in cash and cash equivalents. We are further strengthening our\nfinancial resilience through a broader and more diversified base of financing\npartners and an extended debt maturity profile. In parallel, we continue to\nbenefit from the support of the EIB, a longstanding strategic partner of the\nCompany.”\n\nDetail of Financing Transactions\n\nMedincell has secured €28 million loan from four European commercial banks.\nThe facilities have a five-year maturity, with monthly or quarterly\namortization of principal, and bear interest in line with current market\nconditions, with no covenant or equity-linked instruments attached. This\nfinancing strengthens the Company’s long-term financial flexibility and\noverall cash profile.\n\nIn parallel, the Company will repay early the first tranche, corresponding to\n€20 million of principal, together with related capitalized interests, of\nits existing €40 million EIB credit facility, by the end of July 2026. Prior\nto the transaction, this tranche was fully repayable at maturity in December\n2027. The remaining €20 million, initially repayable in half in January 2028\nand July 2028, will shift to a partial amortizing profile. The Company will\nrepay €200,000 monthly of principal together with a 5% cash interest, with a\nfinal one-off repayment of €17.5 million in July 2028. The transaction is\nexpected to reduce the total financial costs associated with EIB financing by\napproximately €1 million over the remaining life of the facilities.\n\nAs a result, the repayment profile becomes more in line with the expected\nincoming cash flows, and the overall debt maturity is extended to July 2031.\n\nEIB debt profile before and after the transaction\n   Nominal amount: Before transaction: After transaction: \n \n \n€40 million outstanding \n€20 million outstanding \n \n€40 million \n EIB Tranches Tranche A €20 million Repayable in full at maturity in December 2027 (with €4.3 million of Fully repaid (including €3.3 million of capitalized interest) \n capitalized interest) \n Tranche B €10 million Repayable in full at maturity in January 2028 (with €1.6 million of €200,000 monthly amortization of principal of newly combined Tranches B and \n capitalized interest) C, together with a 5% cash interest, leading to a final €17.5 million bullet \n repayment in July 2028 \n Tranche C €10 million Repayable in full at maturity in July 2028 (with €1.6 million of capitalized \n interest) \n\n\nDetailed terms of the initial EIB financing, including its remuneration and\nassociated warrants, are described in the Company’s press release dated\nNovember 23, 2022:\nhttps://www.medincell.com/wp-content/uploads/2024/03/20221123_PR-MdC-EIB-signature_EN.pdf\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2024%2F03%2F20221123_PR-MdC-EIB-signature_EN.pdf&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2024%2F03%2F20221123_PR-MdC-EIB-signature_EN.pdf&index=1&md5=1f8e8da1f3fdc2596d281c97d4dd6880)\n\nThese terms have subsequently been supplemented by the press release\nannouncing the waiver of the warrants put option dated March 26, 2026:\nhttps://www.medincell.com/wp-content/uploads/2026/03/PR_MDC_BEI_EN_260326.pdf\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2026%2F03%2FPR_MDC_BEI_EN_260326.pdf&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2026%2F03%2FPR_MDC_BEI_EN_260326.pdf&index=2&md5=261a835019703dffea0d920126237ea6)\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enables controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023, and\nsubsequently for Bipolar I Disorder in October 2025. It is marketed in the\nUnited States by Teva under the brand name UZEDY(®). Medincell’s\nrisperidone LAI was also approved for schizophrenia in Canada and South Korea\nin 2025.\n\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment\nfor schizophrenia in adults was submitted to the U.S. FDA in December 2025 by\nMedincell’s partner, Teva. U.S. FDA accepted Teva’s New NDA for Olanzapine\nLAI on February 20, 2026. A European Marketing Authorization Application (MAA)\nwas also accepted by EMA in May 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 150 people\nrepresenting more than 27 nationalities.\n\nmedincell.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmedincell.com&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=medincell.com&index=3&md5=d8abd47334bce8a10728f78ca83f3d55)\n\nUZEDY(®) is a trademark of Teva Pharmaceuticals. Medincell’s BEPO(®)\ntechnology is licensed to Teva as SteadyTeq™, a trademark of Teva\nPharmaceuticals.\n\nThis press release contains forward-looking statements, including statements\nregarding Company’s expectations for (i) the timing, progress and outcome of\nits clinical trials; (ii) the clinical benefits and competitive positioning of\nits product candidates; (iii) its ability to obtain regulatory approvals,\ncommence commercial production and achieve market penetration and sales; (iv)\nits future product portfolio; (v) its future partnering arrangements; (vi) its\nfuture capital needs, capital expenditure plans and ability to obtain funding;\nand (vii) prospective financial matters regarding our business. Although the\nCompany believes that its expectations are based on reasonable assumptions,\nany statements other than statements of historical facts that may be contained\nin this press release relating to future events are forward-looking statements\nand subject to change without notice, factors beyond the Company's control and\nthe Company's financial capabilities.\n\nThese statements may include, but are not limited to, any statement beginning\nwith, followed by or including words or phrases such as \"objective\",\n\"believe\", \"anticipate\", “expect”, \"foresee\", \"aim\", \"intend\", \"may\",\n\"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\",\n“potential”, \"should\", \"could\" and other words and phrases of the same\nmeaning or used in negative form. Forward-looking statements are subject to\ninherent risks and uncertainties beyond the Company's control that may, if\nany, cause actual results, performance, or achievements to differ materially\nfrom those anticipated or expressed explicitly or implicitly by such\nforward-looking statements. A list and description of these risks,\ncontingencies and uncertainties can be found in the documents filed by the\nCompany with the Autorité des Marchés Financiers (the \"AMF\") pursuant to its\nregulatory obligations, including the Company's universal registration\ndocument, filed with the AMF on July 29, 2025, under number D. 25-0580 (the\n\"Universal Registration Document\"), as well as in the documents and reports to\nbe published subsequently by the Company. In particular, readers' attention is\ndrawn to the section entitled \"Facteurs de Risques\" on page 30 of the\nRegistration Document.\n\nAny forward-looking statements made by or on behalf of the Company speak only\nas of the date they are made. Except as required by law, the Company does not\nundertake any obligation to publicly update these forward-looking statements\nor to update the reasons why actual results could differ materially from those\nanticipated by the forward-looking statements, including in the event that new\ninformation becomes available. The Company's update of one or more\nforward-looking statements does not imply that the Company will make any\nfurther updates to such forward-looking statements or other forward-looking\nstatements. Readers are cautioned not to place undue reliance on these\nforward-looking statements.\n\nThis press release is for information purposes only. The information contained\nherein does not constitute an offer to sell or a solicitation of an offer to\nbuy or subscribe for the Company's shares in any jurisdiction, in particular\nin France. Similarly, this press release does not constitute investment advice\nand should not be treated as such. It is not related to the investment\nobjectives, financial situation, or specific needs of any recipient. It should\nnot deprive the recipients of the opportunity to exercise their own judgment.\nAll opinions expressed in this document are subject to change without notice.\nThe distribution of this press release may be subject to legal restrictions in\ncertain jurisdictions.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260715956695/en/\n(https://www.businesswire.com/news/home/20260715956695/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwhpsgfa","title":"Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory","author":"Business Wire","ticker":"MEDCL","created":"2026-07-15T15:45:00.093Z","tickers":["MEDCL"],"exchange":"Euronext Paris","article_body":"Medincell Aligns Debt Maturity With Its Expected Revenue Growth Trajectory\n\nMore than 3 years extension of debt maturity to mid-2031, aligning it with\nexpected revenue ramp-up primarily driven by marketed UZEDY(®) and Olanzapine\nLAI, which is currently under regulatory review in the U.S. and Europe\n\n€28 million in non-dilutive new bank loans secured from leading European\ncommercial banks\n\nEarly repayment of half of the €40 million European Investment Bank (EIB)\ncredit facility and the related capitalized interest, originally maturing in\nDecember 2027\n\nRegulatory News:\n\nMedincell (Euronext Paris: MEDCL) today announced the completion of\nnon-dilutive financing transactions designed to strengthen its financing\nprofile and align debt maturities with the Company's expected revenue growth\ntrajectory and future cash flows. These cash flows are expected to be\nprimarily driven by milestones and royalties from UZEDY(®), which is already\nmarketed, and from Olanzapine LAI, currently under regulatory review in the\nU.S., with approval anticipated in Q4 2026. Both products are partnered with\nTeva.\n\nThe Company has secured €28 million in non-dilutive loans with leading\nEuropean commercial banks, with no covenant or equity-linked instruments\nattached, strengthening its long-term cash position. In parallel, the Company\nwill repay a €20 million tranche, together with related capitalized\ninterests, of its existing €40 million European Investment Bank (EIB) credit\nfacility entered into in 2022, by the end of July 2026.\n\nChristophe Douat, CEO of Medincell, said: “This is a natural step in\nexecuting our ‘Shift to Growth’ strategy. As UZEDY sales continue to ramp\nup and we move closer to the potential commercial launch of Olanzapine LAI by\nour partner Teva, we are aligning our financial structure with our expected\nrevenue growth. This strengthens our flexibility and supports the continued\nadvancement of our pipeline of innovative products, aimed at generating\nrecurring, high-margin revenues over time and creating sustainable long-term\nvalue.”\n\nStéphane Postic, CFO of Medincell, said: “These non-dilutive debt financing\ntransactions reflect the continued execution of a long-term financing strategy\naligned with Medincell’s growth trajectory. As of March 31, 2026, we held\n€84.8 million in cash and cash equivalents. We are further strengthening our\nfinancial resilience through a broader and more diversified base of financing\npartners and an extended debt maturity profile. In parallel, we continue to\nbenefit from the support of the EIB, a longstanding strategic partner of the\nCompany.”\n\nDetail of Financing Transactions\n\nMedincell has secured €28 million loan from four European commercial banks.\nThe facilities have a five-year maturity, with monthly or quarterly\namortization of principal, and bear interest in line with current market\nconditions, with no covenant or equity-linked instruments attached. This\nfinancing strengthens the Company’s long-term financial flexibility and\noverall cash profile.\n\nIn parallel, the Company will repay early the first tranche, corresponding to\n€20 million of principal, together with related capitalized interests, of\nits existing €40 million EIB credit facility, by the end of July 2026. Prior\nto the transaction, this tranche was fully repayable at maturity in December\n2027. The remaining €20 million, initially repayable in half in January 2028\nand July 2028, will shift to a partial amortizing profile. The Company will\nrepay €200,000 monthly of principal together with a 5% cash interest, with a\nfinal one-off repayment of €17.5 million in July 2028. The transaction is\nexpected to reduce the total financial costs associated with EIB financing by\napproximately €1 million over the remaining life of the facilities.\n\nAs a result, the repayment profile becomes more in line with the expected\nincoming cash flows, and the overall debt maturity is extended to July 2031.\n\nEIB debt profile before and after the transaction\n   Nominal amount: Before transaction: After transaction: \n \n \n€40 million outstanding \n€20 million outstanding \n \n€40 million \n EIB Tranches Tranche A €20 million Repayable in full at maturity in December 2027 (with €4.3 million of Fully repaid (including €3.3 million of capitalized interest) \n capitalized interest) \n Tranche B €10 million Repayable in full at maturity in January 2028 (with €1.6 million of €200,000 monthly amortization of principal of newly combined Tranches B and \n capitalized interest) C, together with a 5% cash interest, leading to a final €17.5 million bullet \n repayment in July 2028 \n Tranche C €10 million Repayable in full at maturity in July 2028 (with €1.6 million of capitalized \n interest) \n\n\nDetailed terms of the initial EIB financing, including its remuneration and\nassociated warrants, are described in the Company’s press release dated\nNovember 23, 2022:\nhttps://www.medincell.com/wp-content/uploads/2024/03/20221123_PR-MdC-EIB-signature_EN.pdf\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2024%2F03%2F20221123_PR-MdC-EIB-signature_EN.pdf&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2024%2F03%2F20221123_PR-MdC-EIB-signature_EN.pdf&index=1&md5=1f8e8da1f3fdc2596d281c97d4dd6880)\n\nThese terms have subsequently been supplemented by the press release\nannouncing the waiver of the warrants put option dated March 26, 2026:\nhttps://www.medincell.com/wp-content/uploads/2026/03/PR_MDC_BEI_EN_260326.pdf\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2026%2F03%2FPR_MDC_BEI_EN_260326.pdf&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=https%3A%2F%2Fwww.medincell.com%2Fwp-content%2Fuploads%2F2026%2F03%2FPR_MDC_BEI_EN_260326.pdf&index=2&md5=261a835019703dffea0d920126237ea6)\n\nAbout Medincell\n\nMedincell is a clinical- and commercial-stage innovation-driven\nbiopharmaceutical company developing and licensing long-acting injectable\ntreatments across multiple therapeutic areas. Our innovative treatments are\ndesigned to ensure adherence to medical prescriptions, enhance the\neffectiveness and accessibility of medicines, and reduce their environmental\nimpact.\n\nThese treatments combine active pharmaceutical ingredients with our\nproprietary BEPO(®) / BEPO(®) Star technologies, which enables controlled\ndrug delivery at therapeutic levels for several days, weeks, or months\nfollowing a subcutaneous or local injection of a small, fully bioresorbable\ndepot.\n\nRisperidone LAI was the first treatment based on BEPO(®) technology to\nreceive FDA approval, initially for schizophrenia in April 2023, and\nsubsequently for Bipolar I Disorder in October 2025. It is marketed in the\nUnited States by Teva under the brand name UZEDY(®). Medincell’s\nrisperidone LAI was also approved for schizophrenia in Canada and South Korea\nin 2025.\n\nA New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment\nfor schizophrenia in adults was submitted to the U.S. FDA in December 2025 by\nMedincell’s partner, Teva. U.S. FDA accepted Teva’s New NDA for Olanzapine\nLAI on February 20, 2026. A European Marketing Authorization Application (MAA)\nwas also accepted by EMA in May 2026.\n\nMedincell’s investigational pipeline includes numerous innovative\ntherapeutic candidates in various stages of development, from formulation to\nPhase 3 clinical trials. We collaborate with leading pharmaceutical companies\nand foundations to advance global health through new treatment options.\n\nHeadquartered in Montpellier, France, Medincell employs over 150 people\nrepresenting more than 27 nationalities.\n\nmedincell.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmedincell.com&esheet=54570916&newsitemid=20260715956695&lan=en-US&anchor=medincell.com&index=3&md5=d8abd47334bce8a10728f78ca83f3d55)\n\nUZEDY(®) is a trademark of Teva Pharmaceuticals. Medincell’s BEPO(®)\ntechnology is licensed to Teva as SteadyTeq™, a trademark of Teva\nPharmaceuticals.\n\nThis press release contains forward-looking statements, including statements\nregarding Company’s expectations for (i) the timing, progress and outcome of\nits clinical trials; (ii) the clinical benefits and competitive positioning of\nits product candidates; (iii) its ability to obtain regulatory approvals,\ncommence commercial production and achieve market penetration and sales; (iv)\nits future product portfolio; (v) its future partnering arrangements; (vi) its\nfuture capital needs, capital expenditure plans and ability to obtain funding;\nand (vii) prospective financial matters regarding our business. Although the\nCompany believes that its expectations are based on reasonable assumptions,\nany statements other than statements of historical facts that may be contained\nin this press release relating to future events are forward-looking statements\nand subject to change without notice, factors beyond the Company's control and\nthe Company's financial capabilities.\n\nThese statements may include, but are not limited to, any statement beginning\nwith, followed by or including words or phrases such as \"objective\",\n\"believe\", \"anticipate\", “expect”, \"foresee\", \"aim\", \"intend\", \"may\",\n\"anticipate\", \"estimate\", \"plan\", \"project\", \"will\", \"may\", \"probably\",\n“potential”, \"should\", \"could\" and other words and phrases of the same\nmeaning or used in negative form. Forward-looking statements are subject to\ninherent risks and uncertainties beyond the Company's control that may, if\nany, cause actual results, performance, or achievements to differ materially\nfrom those anticipated or expressed explicitly or implicitly by such\nforward-looking statements. A list and description of these risks,\ncontingencies and uncertainties can be found in the documents filed by the\nCompany with the Autorité des Marchés Financiers (the \"AMF\") pursuant to its\nregulatory obligations, including the Company's universal registration\ndocument, filed with the AMF on July 29, 2025, under number D. 25-0580 (the\n\"Universal Registration Document\"), as well as in the documents and reports to\nbe published subsequently by the Company. In particular, readers' attention is\ndrawn to the section entitled \"Facteurs de Risques\" on page 30 of the\nRegistration Document.\n\nAny forward-looking statements made by or on behalf of the Company speak only\nas of the date they are made. Except as required by law, the Company does not\nundertake any obligation to publicly update these forward-looking statements\nor to update the reasons why actual results could differ materially from those\nanticipated by the forward-looking statements, including in the event that new\ninformation becomes available. The Company's update of one or more\nforward-looking statements does not imply that the Company will make any\nfurther updates to such forward-looking statements or other forward-looking\nstatements. Readers are cautioned not to place undue reliance on these\nforward-looking statements.\n\nThis press release is for information purposes only. The information contained\nherein does not constitute an offer to sell or a solicitation of an offer to\nbuy or subscribe for the Company's shares in any jurisdiction, in particular\nin France. Similarly, this press release does not constitute investment advice\nand should not be treated as such. It is not related to the investment\nobjectives, financial situation, or specific needs of any recipient. It should\nnot deprive the recipients of the opportunity to exercise their own judgment.\nAll opinions expressed in this document are subject to change without notice.\nThe distribution of this press release may be subject to legal restrictions in\ncertain jurisdictions.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260715956695/en/\n(https://www.businesswire.com/news/home/20260715956695/en/)\n\nDavid Heuzé \n\nHead of Corporate and Financial Communications, and ESG\n\ndavid.heuze@Medincell.com (mailto:david.heuze@Medincell.com) / +33 (0)6 83 25\n21 86\n\nGrace Kim \n\nChief Strategy Officer, U.S. Finance\n\ngrace.kim@medincell.com (mailto:grace.kim@medincell.com) / +1 (646) 991-4023\n\nNicolas Mérigeau / Gaëlle Fromaigeat \n\nMedia Relations\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\nLouis-Victor Delouvrier / Alban Dufumier \n\nInvestor Relations France\n\nMedincell@newcap.eu (mailto:Medincell@newcap.eu) / +33 (0)1 44 71 94 94\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-15T15:45:00.165743048Z","server_sent_at_ms":1784130300165},"received_at":"2026-07-15T15:45:00.345Z","source_url":"https://www.businesswire.com/news/home/20260715956695/en/"},"analysis":{"id":"78508","press_release_id":"89455","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"debt_offering","narrative":"Medincell secured €28 million in non-dilutive bank loans and extended its debt maturity profile to mid-2031, aligning its financial structure with expected revenue from UZEDY and the potential launch of Olanzapine LAI.\n\nThe company will repay a €20 million tranche of its existing EIB facility early, reducing financial costs by approximately €1 million, while maintaining a strong cash position of €84.8 million.\n\nNew financing carries no covenants or equity-linked instruments, providing operational flexibility ahead of the anticipated Q4 2026 regulatory approval for Olanzapine LAI.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Biotech solidifies balance sheet with non-dilutive funding ahead of key Olanzapine LAI decision."},"keyFigures":{"customDimensions":{"new_debt_eur":"€28 million","cost_savings_eur":"€1 million","cash_position_eur":"€84.8 million","eib_repayment_eur":"€20 million","debt_maturity_extension":"mid-2031"}},"quotedText":"This is a natural step in executing our ‘Shift to Growth’ strategy.","namedEntities":{"people":[{"name":"Christophe Douat","role":"CEO"},{"name":"Stéphane Postic","role":"CFO"}],"products":["UZEDY","Olanzapine LAI","BEPO"],"companies":[{"name":"Medincell","ticker":"MEDCL"},{"name":"Teva","relationship":"partner"},{"name":"European Investment Bank","relationship":"lender"}],"dollarAmounts":[{"amount":"€28 million","context":"new non-dilutive loans from commercial banks"},{"amount":"€40 million","context":"existing EIB credit facility total"},{"amount":"€20 million","context":"early repayment tranche of EIB facility"},{"amount":"€84.8 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"€1 million","context":"expected reduction in total financial costs"},{"amount":"€200,000","context":"monthly principal repayment under new EIB structure"},{"amount":"€17.5 million","context":"final bullet repayment of EIB facility in July 2028"}]},"materialImpact":{"score":3,"reasoning":"The company significantly extended its debt maturity to 2031 and secured €28 million in non-dilutive funding, which strengthens its balance sheet and aligns liabilities with the expected commercial ramp of UZEDY and the potential launch of Olanzapine LAI."},"tickerRelevance":{"others":[],"primary":"MEDCL"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid_cap","eventGravity":"balance_sheet_strengthening","sectorWeight":"biotech"}},"event_type":"debt_offering","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Medincell secured €28 million in non-dilutive bank loans and extended its debt maturity profile to mid-2031, aligning its financial structure with expected revenue from UZEDY and the potential launch of Olanzapine LAI.\n\nThe company will repay a €20 million tranche of its existing EIB facility early, reducing financial costs by approximately €1 million, while maintaining a strong cash position of €84.8 million.\n\nNew financing carries no covenants or equity-linked instruments, providing operational flexibility ahead of the anticipated Q4 2026 regulatory approval for Olanzapine LAI.","key_figures":{"customDimensions":{"new_debt_eur":"€28 million","cost_savings_eur":"€1 million","cash_position_eur":"€84.8 million","eib_repayment_eur":"€20 million","debt_maturity_extension":"mid-2031"}},"named_entities":{"people":[{"name":"Christophe Douat","role":"CEO"},{"name":"Stéphane Postic","role":"CFO"}],"products":["UZEDY","Olanzapine LAI","BEPO"],"companies":[{"name":"Medincell","ticker":"MEDCL"},{"name":"Teva","relationship":"partner"},{"name":"European Investment Bank","relationship":"lender"}],"dollarAmounts":[{"amount":"€28 million","context":"new non-dilutive loans from commercial banks"},{"amount":"€40 million","context":"existing EIB credit facility total"},{"amount":"€20 million","context":"early repayment tranche of EIB facility"},{"amount":"€84.8 million","context":"cash and cash equivalents as of March 31, 2026"},{"amount":"€1 million","context":"expected reduction in total financial costs"},{"amount":"€200,000","context":"monthly principal repayment under new EIB structure"},{"amount":"€17.5 million","context":"final bullet repayment of EIB facility in July 2028"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-15T19:28:43.677Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-mid_cap","eventGravity":"balance_sheet_strengthening","sectorWeight":"biotech"}},"durationMs":304719,"modelName":"glm-4.7"}}